Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
J Infect Dis
; 215(12): 1807-1815, 2017 06 15.
Article
em En
| MEDLINE
| ID: mdl-28472421
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Replicação Viral
/
Infecções por Coronavirus
/
Dipeptidil Peptidase 4
/
Anticorpos Neutralizantes
/
Coronavírus da Síndrome Respiratória do Oriente Médio
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article